Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were shown to exhibit higher proliferative activity, greater chemo- and radioresistance, and enhanced tumorigenicity compared to their CD133-negative counterparts. For this reason, CD133 is regarded as a potential prognostic biomarker in oncology. The CD133-positive cells are related to the cancer stem cell subpopulation in many types of cancer. Recent studies demonstrated the involvement of CD133 in the regulation of proliferation, autophagy, and apoptosis in cancer cells. There is also evidence of its participation in the epithelial–mesenchymal transition associated with tumor progression. For a number of malignant tumor types, high CD133 expression is associated with poor prognosis, and the prognostic significance of CD133 has been confirmed in a number of meta-analyses. However, some published papers suggest that CD133 has no prognostic significance or even demonstrate a certain correlation between high CD133 levels and a positive prognosis. This review summarizes and discusses the existing evidence for and against the prognostic significance of CD133 in cancer. We also consider possible reasons for conflicting findings from the studies of the clinical significance of CD133.

[1]  M. Kucińska,et al.  Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets , 2023, International journal of molecular sciences.

[2]  Y. Miyagi,et al.  Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer , 2023, AntiCancer Research.

[3]  K. Yamashita,et al.  Less demand on stem cell marker-positive cancer cells may characterize metastasis of colon cancer , 2023, PloS one.

[4]  A. Nakagawara,et al.  Molecular Regulation of Autophagy and Asymmetric Cell Division by Cancer Stem Cell Marker CD133 , 2023, Cells.

[5]  K. Yarygin,et al.  Telomeres and Telomerase in the Control of Stem Cells , 2022, Biomedicines.

[6]  A. Kopylov,et al.  TRIM28 Is a Novel Regulator of CD133 Expression Associated with Cancer Stem Cell Phenotype , 2022, International journal of molecular sciences.

[7]  Niannian Liu,et al.  CEACAM5 targeted by miR-498 promotes cell proliferation, migration and epithelial to mesenchymal transition in gastric cancer , 2022, Translational oncology.

[8]  J. Duyster,et al.  Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. , 2022, Cancer letters.

[9]  Cuiping Yang,et al.  Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation , 2022, Cell Death & Differentiation.

[10]  R. Pei,et al.  Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer. , 2022, Journal of materials chemistry. B.

[11]  Reena Philip,et al.  FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jian Wu,et al.  Effects of CD133 expression on chemotherapy and drug sensitivity of adenoid cystic carcinoma , 2021, Molecular medicine reports.

[13]  V. M. P. Pereira,et al.  Cancerous and non-neoplastic stem cells in the stomach similarly express CD44 and CD133. , 2021, Acta histochemica.

[14]  Parul Gupta,et al.  Expression of CD44 and CD133 stem cell markers in squamous cell carcinoma of esophagus , 2021, Indian journal of pathology & microbiology.

[15]  V. Zgoda,et al.  CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells. , 2021, Cancer biomarkers : section A of Disease markers.

[16]  K. N. Yarygin,et al.  Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs , 2021, Bulletin of Experimental Biology and Medicine.

[17]  M. Waligóra,et al.  CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion , 2021, Journal of clinical medicine.

[18]  H. Salih,et al.  An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia , 2021, Cancers.

[19]  T. Ozaki,et al.  CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt‐mediated protein synthesis and inhibition of apoptosis , 2021, FEBS open bio.

[20]  T. Tongtawee,et al.  Co-Expression of LGR5 and CD133 Cancer Stem Cell Predicts a Poor Prognosis in Patients With Gastric Cancer. , 2021, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[21]  Y. Xuan,et al.  Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy , 2021, Cancer Immunology, Immunotherapy.

[22]  S. Weissman,et al.  Colorectal Cancer Stem Cell States Uncovered by Simultaneous Single‐Cell Analysis of Transcriptome and Telomeres , 2021, Advanced science.

[23]  J. Bartek,et al.  Expression of the stem cell marker CD133 in malignant meningioma. , 2020, Clinical neuropathology.

[24]  B. Baradaran,et al.  The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  Mohamed Hassan,et al.  Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways , 2020, Oncogene.

[26]  Zhen-Bin Ma,et al.  Characterisation of a subpopulation of CD133+ cancer stem cells from Chinese patients with oral squamous cell carcinoma , 2020, Scientific Reports.

[27]  J. Moffat,et al.  The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. , 2020, Cell stem cell.

[28]  Zhe Zhang,et al.  Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells , 2020, BMC Cancer.

[29]  Xuewen Li,et al.  CD133 expressionand clinicopathologic significance in benign and malignant breast lesions. , 2020, Cancer biomarkers : section A of Disease markers.

[30]  D. Ribatti,et al.  Epithelial-Mesenchymal Transition in Cancer: A Historical Overview , 2020, Translational oncology.

[31]  Hamid Cheshomi,et al.  Prognostic and Clinical Value of CD44 and CD133 in Esophageal Cancer: A Systematic Review and Meta-analysis. , 2020, Iranian journal of allergy, asthma, and immunology.

[32]  S. Antović,et al.  High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer. , 2020, Polski przeglad chirurgiczny.

[33]  Yijun Kang,et al.  The prognostic role of CD133 expression in patients with osteosarcoma , 2020, Clinical and Experimental Medicine.

[34]  H. Abdollahi,et al.  Cancer stem cells: A review from origin to therapeutic implications , 2020, Journal of cellular physiology.

[35]  K. Majidzadeh-A,et al.  Enrichment of cancer stem‐like cells by the induction of epithelial‐mesenchymal transition using lentiviral vector carrying E‐cadherin shRNA in HT29 cell line , 2019, Journal of cellular physiology.

[36]  P. Nelson,et al.  Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer , 2019, Clinical Cancer Research.

[37]  Junsoo Park,et al.  CRISPR-Cas9 mediated CD133 knockout inhibits colon cancer invasion through reduced epithelial-mesenchymal transition , 2019, PloS one.

[38]  H. Clevers,et al.  Defining Adult Stem Cell Function at Its Simplest: The Ability to Replace Lost Cells through Mitosis. , 2019, Cell stem cell.

[39]  K. Yarygin,et al.  Proliferative Activity of Colorectal Cancer Cells with Different Levels of CD133 Expression , 2019, Bulletin of Experimental Biology and Medicine.

[40]  G. Pearson,et al.  Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis , 2019, Journal of clinical medicine.

[41]  W. Liu,et al.  CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression. , 2019, Biochemical and biophysical research communications.

[42]  M. Arafa,et al.  Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma , 2019, Pathologica.

[43]  A. Nakagawara,et al.  Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region , 2019, Scientific Reports.

[44]  I. Ellis,et al.  Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer , 2018, Breast Cancer Research and Treatment.

[45]  B. Rueda,et al.  PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells , 2018, Molecular Cancer Research.

[46]  J. Chiang,et al.  Surface Molecular Markers of Cancer Stem Cells: Computation Analysis of Full-Text Scientific Articles , 2018, Bulletin of Experimental Biology and Medicine.

[47]  Prabhaker Mishra,et al.  Prognostic Value of Cancer Stem Cell Markers in Potentially Malignant Disorders of Oral Mucosa: A Meta-analysis , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[48]  Jian-Hui Huang,et al.  Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis , 2018, Journal of cancer research and therapeutics.

[49]  A. LeBeau,et al.  The identification of a novel antibody for CD133 using human antibody phage display , 2018, The Prostate.

[50]  Kyung-Hee Kim,et al.  Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma , 2018, AntiCancer Research.

[51]  P. Meltzer,et al.  Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells , 2018, Molecular Cancer Therapeutics.

[52]  Junrong Wu,et al.  CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients , 2018, Medicine.

[53]  Zhiqiang Wu,et al.  CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial , 2018, Oncoimmunology.

[54]  Yifeng Tao,et al.  Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies , 2018, Cellular Physiology and Biochemistry.

[55]  S. Dooley,et al.  CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma , 2018, Journal of Translational Medicine.

[56]  C. Shang,et al.  Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells , 2018, Cancer biology & therapy.

[57]  S. Ishihara,et al.  CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis , 2018, International journal of oncology.

[58]  D. Corbeil,et al.  Prominin‐1/CD133: Lipid Raft Association, Detergent Resistance, and Immunodetection , 2017, Stem cells translational medicine.

[59]  Do Hyung Kim,et al.  Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview , 2017, Journal of clinical medicine.

[60]  Shugang Li,et al.  The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis. , 2017, Future oncology.

[61]  M. Abolhasani,et al.  Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma. , 2017, Experimental and molecular pathology.

[62]  H. Harada,et al.  Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry , 2017, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[63]  B. Lloveras,et al.  Prognostic impact of CD133 expression in Endometrial Cancer Patients , 2017, Scientific Reports.

[64]  Wei-Chieh Huang,et al.  The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients , 2017, BMC Cancer.

[65]  K. N. Yarygin,et al.  Cancer stem cell molecular markers verified in vivo , 2017, Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.

[66]  H. Kim,et al.  Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133 , 2017, Scientific Reports.

[67]  S. Mayor,et al.  The mystery of membrane organization: composition, regulation and roles of lipid rafts , 2017, Nature Reviews Molecular Cell Biology.

[68]  N. Shen,et al.  Expression of CD133, E-cadherin and WWOX in colorectal cancer and related analysis , 2017, Pakistan journal of medical sciences.

[69]  Juan Wang,et al.  Prognostic Value of Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma: a Meta-analysis , 2017, Scientific Reports.

[70]  Dexi Chen,et al.  CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma , 2017, Scientific Reports.

[71]  Menglin Wu,et al.  Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer , 2016, Medicine.

[72]  Bo Cheng,et al.  Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis , 2016, Oncotarget.

[73]  Zhangfa Song,et al.  The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis , 2016, Oncotarget.

[74]  Donghwi Kim,et al.  Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines , 2016, Clinical & Experimental Metastasis.

[75]  Hui Yang,et al.  High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma , 2016, Molecular Neurobiology.

[76]  Xin-hua Liang,et al.  CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation , 2016, Oncotarget.

[77]  M. Moradi-Lakeh,et al.  Expression of CD133 Cancer Stem Cell Marker in Melanoma: A Systematic Review and Meta-Analysis , 2016, The International journal of biological markers.

[78]  Chen Li,et al.  CD133 promotes gallbladder carcinoma cell migration through activating Akt phosphorylation , 2016, Oncotarget.

[79]  Jiang Li,et al.  CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis , 2016, Oncotarget.

[80]  D. Geller,et al.  Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells , 2015, Oncotarget.

[81]  S. Nam,et al.  Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53 , 2015, Cell Death and Disease.

[82]  Yiming Li,et al.  CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: A systematic review and meta-analysis , 2015, Oncotarget.

[83]  Leizhen Zheng,et al.  Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. , 2015, International journal of clinical and experimental pathology.

[84]  K. Nan,et al.  Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma , 2015, Medicine.

[85]  B. Guo,et al.  [Expressions of CD133, E-cadherin, and Snail in epithelial ovarian cancer and their clinicopathologic and prognostic implications]. , 2015, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[86]  L. Pardo,et al.  CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells , 2015, PloS one.

[87]  C. Liang,et al.  An aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype , 2015, Oncogenesis.

[88]  Haibin Xia,et al.  Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody. , 2015, Oncology letters.

[89]  A. Hampl,et al.  Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines , 2015, International journal of molecular medicine.

[90]  M. Ge,et al.  Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis , 2015, Journal of experimental & clinical cancer research : CR.

[91]  Y. Liu,et al.  Mutation of N-linked glycosylation at Asn548 in CD133 decreases its ability to promote hepatoma cell growth , 2015, Oncotarget.

[92]  C. Zhong,et al.  Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis , 2015, Tumor Biology.

[93]  Zhiqing Liang,et al.  CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition , 2015, Oncotarget.

[94]  Jian Feng,et al.  High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer , 2015, Disease markers.

[95]  A. Hjelmeland,et al.  Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells , 2014, PloS one.

[96]  S. Millar,et al.  CD133 expression correlates with membrane beta-catenin and e-cadherin loss from human hair follicle placodes during morphogenesis , 2014, The Journal of investigative dermatology.

[97]  Yan Zhou,et al.  The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis , 2014, Tumor Biology.

[98]  X. Bian,et al.  Is CD133 Expression a Prognostic Biomarker of Non-Small-Cell Lung Cancer? A Systematic Review and Meta-Analysis , 2014, PloS one.

[99]  W. Huttner,et al.  Human Prominin-1 (CD133) Is Detected in Both Neoplastic and Non-Neoplastic Salivary Gland Diseases and Released into Saliva in a Ubiquitinated Form , 2014, PloS one.

[100]  J. Moffat,et al.  Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. , 2014, Journal of molecular biology.

[101]  L. Goodell,et al.  Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133+ Tumor-Initiating Cells , 2014, PloS one.

[102]  S. Takao,et al.  CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis , 2014, Molecular Cancer.

[103]  R. Luo,et al.  Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. , 2013, International journal of clinical and experimental pathology.

[104]  Jiayin Yang,et al.  Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis , 2013, European journal of gastroenterology & hepatology.

[105]  M. Rinaldo,et al.  Nuclear Localization of Cancer Stem Cell Marker CD133 in Triple-Negative Breast Cancer: A Case Report , 2013, Tumori.

[106]  Xiang Du,et al.  CD133: a cancer stem cells marker, is used in colorectal cancers. , 2013, World journal of gastroenterology.

[107]  N. Normanno,et al.  TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction , 2013, Cell Death and Disease.

[108]  Y. Liu,et al.  Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells , 2013, Proceedings of the National Academy of Sciences.

[109]  S. Chang,et al.  CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy , 2013, BMC Cancer.

[110]  L. Donovan,et al.  CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. , 2013, International journal of oncology.

[111]  Hongyang Wang,et al.  CD133/Prominin-1-Mediated Autophagy and Glucose Uptake Beneficial for Hepatoma Cell Survival , 2013, PloS one.

[112]  Shicai Chen,et al.  CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[113]  D. Corbeil,et al.  CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges , 2013, The Journal of pathology.

[114]  P. Álvarez,et al.  MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy , 2012, Journal of Translational Medicine.

[115]  Jian Huang,et al.  Prognostic role of CD133 expression in colorectal cancer: a meta-analysis , 2012, BMC Cancer.

[116]  A. Gingras,et al.  Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. , 2012, Cell reports.

[117]  N. Potter,et al.  A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles. , 2012, Translational oncology.

[118]  D. Hwang,et al.  CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. , 2012, Cancer letters.

[119]  S. Mocellin,et al.  Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis , 2012, Annals of Surgical Oncology.

[120]  A. Unterberg,et al.  Expression and regulation of AC133 and CD133 in glioblastoma , 2011, Glia.

[121]  S. Natsugoe,et al.  Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial–mesenchymal transition in pancreatic cancer , 2011, Human Cell.

[122]  Hyung-Seok Kim,et al.  The presence of stem cell marker‐expressing cells is not prognostically significant in glioblastomas , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[123]  D. Corbeil,et al.  CD133 and membrane microdomains: old facets for future hypotheses. , 2011, World Journal of Gastroenterology.

[124]  H. Ueno,et al.  Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. , 2011, International journal of oncology.

[125]  J. Moffat,et al.  CD133 Protein N-Glycosylation Processing Contributes to Cell Surface Recognition of the Primitive Cell Marker AC133 Epitope* , 2011, The Journal of Biological Chemistry.

[126]  Yi-Wei Chen,et al.  Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells , 2011, Cancer.

[127]  R. Qin,et al.  CD133(+) gallbladder carcinoma cells exhibit self-renewal ability and tumorigenicity. , 2011, World journal of gastroenterology.

[128]  D. Lingwood,et al.  Cholesterol modulates glycolipid conformation and receptor activity. , 2011, Nature chemical biology.

[129]  B. Kristensen,et al.  Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[130]  S. Kyo,et al.  Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. , 2010, Human pathology.

[131]  C. Forster,et al.  Identification of a novel monoclonal antibody recognizing CD133. , 2010, Journal of immunological methods.

[132]  C. Eberhart,et al.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.

[133]  L. del Vecchio,et al.  The percentage of CD133+ cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection , 2010, BMC Cancer.

[134]  Robert E. Brown,et al.  Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. , 2010, Annals of clinical and laboratory science.

[135]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[136]  G. Stassi,et al.  The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. , 2010, Cancer research.

[137]  D. Roberts,et al.  CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.

[138]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[139]  J. Fantini,et al.  The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. , 2009, Cancer letters.

[140]  I. Bisson,et al.  WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics , 2009, Cell Research.

[141]  Austin G Smith,et al.  CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent , 2009, PloS one.

[142]  S. Rafii,et al.  SURROGATE MARKERS PREDICT ANGIOGENIC POTENTIAL AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME , 2009, Neurosurgery.

[143]  K. Camphausen,et al.  Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro , 2009, Molecular Cancer Research.

[144]  Nicolò Riggi,et al.  Identification of cancer stem cells in Ewing's sarcoma. , 2009, Cancer research.

[145]  C. Cavaliere,et al.  Correction: Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours , 2008, PLoS ONE.

[146]  L. Ricci-Vitiani,et al.  Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[147]  D. Benos,et al.  CD133 Is a Marker of Bioenergetic Stress in Human Glioma , 2008, PloS one.

[148]  C. Cavaliere,et al.  Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours , 2008, PloS one.

[149]  W. Huttner,et al.  The Stem Cell Marker CD133 (Prominin-1) Is Expressed in Various Human Glandular Epithelia , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[150]  B. Kristensen,et al.  CD133 identifies perivascular niches in grade II–IV astrocytomas , 2008, Journal of Neuro-Oncology.

[151]  D. Gisselsson,et al.  Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.

[152]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[153]  A. Molven,et al.  Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas , 2008, BMC Cancer.

[154]  D. Wion,et al.  Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. , 2007, Cancer letters.

[155]  W. Huttner,et al.  Focus on molecules: prominin-1 (CD133). , 2007, Experimental eye research.

[156]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[157]  Hua Zhao,et al.  Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence , 2007, Cancer.

[158]  D. Corbeil,et al.  GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells , 2007, FEBS letters.

[159]  Jianren Gu,et al.  CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity , 2007, International journal of cancer.

[160]  D. Häussinger,et al.  CD133+ hepatic stellate cells are progenitor cells. , 2007, Biochemical and biophysical research communications.

[161]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[162]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[163]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[164]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[165]  W. Huttner,et al.  Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells , 2005, Journal of Cell Science.

[166]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.

[167]  S. Rafii,et al.  AC133/CD133/Prominin-1. , 2005, The international journal of biochemistry & cell biology.

[168]  K. Boheler,et al.  Somatic Stem Cell Marker Prominin‐1/CD133 Is Expressed in Embryonic Stem Cell–Derived Progenitors , 2005, Stem cells.

[169]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[170]  W. Huttner,et al.  Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis , 2004, Journal of Cell Science.

[171]  C. Robson,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[172]  Giulio Cossu,et al.  Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. , 2004, The Journal of clinical investigation.

[173]  D. Ribatti The involvement of endothelial progenitor cells in tumor angiogenesis , 2004, Journal of cellular and molecular medicine.

[174]  S. Rafii,et al.  Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. , 2004, Blood.

[175]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[176]  W. Huttner,et al.  Characterization of Prominin-2, a New Member of the Prominin Family of Pentaspan Membrane Glycoproteins* 210 , 2003, The Journal of Biological Chemistry.

[177]  H. Frank,et al.  Monoclonal Antibody CD133–2 (AC141) Against Hematopoietic Stem Cell Antigen CD133 Shows Crossreactivity with Cytokeratin 18 , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[178]  I. Weissman,et al.  Direct isolation of human central nervous system stem cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[179]  W. Huttner,et al.  Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane , 2000, Nature Cell Biology.

[180]  W. Huttner,et al.  The Human AC133 Hematopoietic Stem Cell Antigen Is also Expressed in Epithelial Cells and Targeted to Plasma Membrane Protrusions* , 2000, The Journal of Biological Chemistry.

[181]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[182]  J. Kearney,et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.

[183]  R. Warnke,et al.  A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. , 1997, Blood.

[184]  W. Huttner,et al.  Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[185]  OUP accepted manuscript , 2022, Stem Cells.

[186]  M. Bandehpour,et al.  An In-silico Approach and Experimental Analysis Combination: Two Strategies for Selecting the third Extracellular Domain (D-EC3) of Human CD133 Marker as a Target for Detection of Cancer Stem Cells , 2021, Iranian journal of pharmaceutical research : IJPR.

[187]  M. Pocard,et al.  CD133 Clinical Trials: Safety and Efficacy , 2019 .

[188]  W. Fang,et al.  Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. , 2018, International journal of clinical and experimental pathology.

[189]  Bin Huang,et al.  Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis , 2014, Molecular Neurobiology.

[190]  N. Maitland,et al.  Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells. , 2013, Advances in experimental medicine and biology.

[191]  Yi-Wei Chen,et al.  Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. , 2013, Oral oncology.

[192]  L. Ricci-Vitiani,et al.  Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis , 2011, Cancer.

[193]  M. Raffeld,et al.  Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. , 2010, Methods in molecular biology.

[194]  S. Raghavendra,et al.  Xylene: An overview of its health hazards and preventive measures , 2010, Journal of oral and maxillofacial pathology : JOMFP.

[195]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[196]  W. Huttner,et al.  Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer , 2004, Cell and Tissue Research.

[197]  W. Huttner,et al.  A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. , 2000, Human molecular genetics.